Projects per year
Personal profile
Personal profile
Jenny Chang, MD, is the Director of the Houston Methodist Dr. Mary and Ron Neal Cancer Center and holds the Emily Herrmann Presidential Distinguished Chair in Cancer Research. She is a Professor of Cancer with the Institute for Academic Medicine and a member of the Houston Methodist Research Institute and Professor at Weill Cornell Medical School. She obtained her medical degree at Cambridge University in England and completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research in the United Kingdom. She was also awarded a research doctorate from the University of London. Her recent work has focused on the intrinsic therapy resistance of cancer stem cells, and the role of targeting inflammatory pathways to change tumor immune microenvironment. Dr. Chang's clinical research aims to evaluate these novel biologic agents in breast cancer patients.
Research interests
Dr. Chang has worked in the field of tumor-initiating cells for more than ten years. After her discovery that tumor-initiating cells are chemo-resistant, and that targeting the EGFR/HER2 pathway can decrease this subpopulation, Dr. Chang has played a key role in demonstrating some of the limitations and mechanisms of tumor-initiating cells (Creighton et al., 2009; Li et al., 2008). Her work is now focused on the mechanisms that regulate TICs, as well as initiating and planning clinical trials that target this critical tumor initiating subpopulation. She is also interested in characterizing the cross-talk between these different pathways that may lead to mechanisms of resistance, and has identified some of the chief regulatory pathways involved in TIC self-renewal. She is a world-renown clinical investigator, credited as one of the first to describe intrinsic chemo-resistance of tumor-initiating cells.
Education/Academic qualification
MD, University of Cambridge
Aug 1 1986 → Dec 18 1990
Award Date: Dec 18 1990
Research Doctorate, University of London
External positions
Professor of Medicine, Weill Cornell Medical College, Cornell University
Research Area Keywords
- Cancer
- Systems Medicine & Bioinformatics
- Clinical Translation & Trials
Free-text keywords
- Cancer
- Stem cells
- Breast cancer
- High throughput
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Dual targeting of PI3K and NOS pathways in Metaplastic Breast Cancer (MBC)
7/8/23 → 6/30/28
Project: Federal Funding Agencies
-
Targeting Nitric Oxide Synthase (NOS) pathway to remodel obesity induced tumor inflammation in patients with TNBC
12/1/22 → 11/30/24
Project: State
-
Rationally designed orally delivered small molecules that disable erbB receptors in Breast cancer
10/1/22 → 9/30/23
Project: Federal Funding Agencies
-
A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC)
6/10/22 → 5/31/27
Project: Federal Funding Agencies
-
A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases
Shah, A. N., Santa-Maria, C. A., Mukhija, D., Shah, N., Kang, A. K., Kumthekar, P., Burdett, K., Chandra, S., Chang, J., Tsarwhas, D., Woodman, J., Jovanovic, B., Gerratana, L., Gradishar, W. & Cristofanilli, M., Apr 2023, In: Clinical Breast Cancer. 23, 3, p. 324-329 6 p.Research output: Contribution to journal › Article › peer-review
-
Interferon-gamma is quintessential for NOS2 and COX2 expression in ER- breast tumors that lead to poor outcome
Cheng, R. Y. S., Ridnour, L. A., Wink, A. L., Gonzalez, A. L., Femino, E. L., Rittscher, H., Somasundaram, V., Heinz, W. F., Coutinho, L., Rangel, M. C., Edmondson, E. F., Butcher, D., Kinders, R. J., Li, X., Wong, S. T. C., McVicar, D. W., Anderson, S. K., Pore, M., Hewitt, S. M., Billiar, T. R., & 5 others , May 11 2023, In: Cell Death and Disease. 14, 5, p. 319 319.Research output: Contribution to journal › Article › peer-review
Open Access -
Targeting Nitric Oxide: Say NO to Metastasis
Reddy, T. P., Glynn, S. A., Billiar, T. R., Wink, D. A. & Chang, J. C., May 15 2023, In: Clinical Cancer Research. 29, 10, p. 1855-1868 14 p.Research output: Contribution to journal › Review article › peer-review
Open Access2 Scopus citations -
A comparative efficacy study of diagnostic digital breast tomosynthesis and digital mammography in BI-RADS 4 breast cancer diagnosis
Ezeana, C. F., Puppala, M., Wang, L., Chang, J. C. & Wong, S. T. C., Aug 2022, In: European Journal of Radiology. 153, p. 110361 110361.Research output: Contribution to journal › Article › peer-review
Open Access -
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Loibl, S., Huang, C. S., Mano, M. S., Mamounas, E. P., Geyer, C. E., Untch, M., Thery, J. C., Schwaner, I., Limentani, S., Loman, N., Lübbe, K., Chang, J. C., Hatschek, T., Tesarowski, D., Song, C., Lysbet de Haas, S., Boulet, T., Lambertini, C. & Wolmark, N., Dec 2022, In: npj Breast Cancer. 8, 1, 106.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations